Innoviva, Inc. HVE.F Stock
Innoviva, Inc. Price Chart
Innoviva, Inc. HVE.F Financial and Trading Overview
| Innoviva, Inc. stock price | 14.9 EUR |
| Previous Close | 11.9 EUR |
| Open | 11.9 EUR |
| Bid | 11.9 EUR x 33200 |
| Ask | 12.1 EUR x 32300 |
| Day's Range | 11.9 - 11.9 EUR |
| 52 Week Range | 9.9 - 15.3 EUR |
| Volume | 34 EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 785.37M EUR |
| Beta (5Y Monthly) | 0.55176 |
| PE Ratio (TTM) | 4.9790792 |
| EPS (TTM) | 2.09 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | September 8, 2015 |
| 1y Target Est | N/A |
HVE.F Valuation Measures
| Enterprise Value | 1.11B EUR |
| Trailing P/E | 4.9790792 |
| Forward P/E | 7.2560973 |
| PEG Ratio (5 yr expected) | 0.48 |
| Price/Sales (ttm) | 2.4724083 |
| Price/Book (mrq) | 1.3950762 |
| Enterprise Value/Revenue | 3.493 |
| Enterprise Value/EBITDA | 6.38 |
Trading Information
Innoviva, Inc. Stock Price History
| Beta (5Y Monthly) | 0.55176 |
| 52-Week Change | -12.50% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 15.3 EUR |
| 52 Week Low | 9.9 EUR |
| 50-Day Moving Average | 11.46 EUR |
| 200-Day Moving Average | 11.89 EUR |
HVE.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 65.5M |
| Float | 53.77M |
| Short Ratio | N/A |
| % Held by Insiders | 0.86% |
| % Held by Institutions | 112.56% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 73.35% |
| Operating Margin (ttm) | 51.77% |
| Gross Margin | 77.23% |
| EBITDA Margin | 54.75% |
Management Effectiveness
| Return on Assets (ttm) | 9.18% |
| Return on Equity (ttm) | 39.01% |
Income Statement
| Revenue (ttm) | 317.65M EUR |
| Revenue Per Share (ttm) | 4.59 EUR |
| Quarterly Revenue Growth (yoy) | -15.19% |
| Gross Profit (ttm) | 276.11M EUR |
| EBITDA | 173.93M EUR |
| Net Income Avi to Common (ttm) | 233.01M EUR |
| Diluted EPS (ttm) | 2.39 |
| Quarterly Earnings Growth (yoy) | 121.00% |
Balance Sheet
| Total Cash (mrq) | 144.05M EUR |
| Total Cash Per Share (mrq) | 2.2 EUR |
| Total Debt (mrq) | 448.06M EUR |
| Total Debt/Equity (mrq) | 79.8 EUR |
| Current Ratio (mrq) | 7.773 |
| Book Value Per Share (mrq) | 8.53 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 129.31M EUR |
| Levered Free Cash Flow (ttm) | 98.34M EUR |
Profile of Innoviva, Inc.
| Country | Germany |
| State | CA |
| City | Burlingame |
| Address | 1350 Old Bayshore Highway |
| ZIP | 94010 |
| Phone | 650 238 9600 |
| Website | https://www.inva.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 101 |
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Q&A For Innoviva, Inc. Stock
What is a current HVE.F stock price?
Innoviva, Inc. HVE.F stock price today per share is 14.9 EUR.
How to purchase Innoviva, Inc. stock?
You can buy HVE.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Innoviva, Inc.?
The stock symbol or ticker of Innoviva, Inc. is HVE.F.
Which industry does the Innoviva, Inc. company belong to?
The Innoviva, Inc. industry is Biotechnology.
How many shares does Innoviva, Inc. have in circulation?
The max supply of Innoviva, Inc. shares is 62.57M.
What is Innoviva, Inc. Price to Earnings Ratio (PE Ratio)?
Innoviva, Inc. PE Ratio is 7.12918660 now.
What was Innoviva, Inc. earnings per share over the trailing 12 months (TTM)?
Innoviva, Inc. EPS is 2.09 EUR over the trailing 12 months.
Which sector does the Innoviva, Inc. company belong to?
The Innoviva, Inc. sector is Healthcare.